Addala Santhinissi, Vissapragada Madhuri, Aggunna Madhumita, Mukala Niharikha, Lanka Manisha, Gampa Shyamkumar, Sodasani Manikanta, Chintalapati Jahnavi, Kamidi Akhila, Veeranna Ravindra P, Yedidi Ravikiran S
Stem Cell Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Synthetic Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.
Vaccines (Basel). 2022 May 25;10(6):841. doi: 10.3390/vaccines10060841.
Coronavirus disease-2019 (COVID-19) is a pandemic with a high morbidity rate occurring over recent years. COVID-19 is caused by the severe acute respiratory syndrome causing coronavirus type-2 (SARS-CoV-2). COVID-19 not only challenged mankind but also gave scope to the evolution of various vaccine design technologies. Although these vaccines protected and saved many lives, with the emerging viral strains, some of the strains may pose a threat to the currently existing vaccine design that is primarily based on the wild type spike protein of SARS-CoV-2. To evaluate the risk involved from such mutant viral strains, we performed a systematic in silico amino acid substitution of critical residues in the receptor binding domain (RBD) of the spike protein. Our molecular modeling analysis revealed significant topological changes in the RBD of spike protein suggesting that they could potentially contribute to the loss of antigen specificity for the currently existing therapeutic antibodies/vaccines, thus posing a challenge to the current vaccine strategies that are based on wild type viral spike protein epitopes. The structural deviations discussed in this article should be considered carefully in the future vaccine design.
2019冠状病毒病(COVID-19)是近年来发病率很高的一种大流行病。COVID-19由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起。COVID-19不仅给人类带来了挑战,也为各种疫苗设计技术的发展提供了空间。尽管这些疫苗保护并拯救了许多生命,但随着新出现的病毒株,其中一些毒株可能会对目前主要基于SARS-CoV-2野生型刺突蛋白的疫苗设计构成威胁。为了评估此类突变病毒株带来的风险,我们对刺突蛋白受体结合域(RBD)中的关键残基进行了系统的计算机模拟氨基酸替换。我们的分子建模分析显示,刺突蛋白的RBD有显著的拓扑变化,这表明它们可能会导致现有治疗性抗体/疫苗的抗原特异性丧失,从而对目前基于野生型病毒刺突蛋白表位的疫苗策略构成挑战。本文讨论的结构偏差在未来疫苗设计中应予以仔细考虑。